Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Initial Results froma Phase 2 Trial of Motesanib Diphosphate (AMG 706) in Patients (pts) with Medullary Thyroid Carcinoma (MTC)

Initial Results froma Phase 2 Trial of Motesanib Diphosphate (AMG 706) in Patients (pts) with Medullary Thyroid Carcinoma (MTC). ENDO Society 2007. 2007; Abstr #852315.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.